BVS

Bioventus's stock price has been impacted by several events in the past six months. The company's stock price reached a new 52-week high after better-than-expected Q1 2026 earnings and raised guidance. Several analysts issued reports on BVS shares, with some boosting price targets and maintaining "Buy" or "Strong Buy" ratings in March 2026. In March 2026, a director sold 12,000 shares of the company's stock for a total value of $105,480.00. Bioventus Inc. was added to the S&P Healthcare Equipment Select Industry Index.